LARAD, Inc. is using virus-like particle technology to produce universal multivalent vaccines and diagnostics for food-animal diseases. The company’s initial focus is on products licensed from The Ohio State University for an immunosuppressive disease in poultry caused by the infectious bursal disease virus. Its genetically engineered universal vaccine can protect against multiple strains of the virus and its flexibility allows new antigens to easily be introduced, allowing it to keep pace with new antigenic changes in the virus.


Location: Northeast Ohio

Technology Sector: Medical

Funding Type: Series A